Whether full recovery of ovarian cancer cell RNR activity, anticipated to facilitate cisplatin-mediated DNA damage repair, is attributable to reversible 3-AP pharmacologic inhibition, 3-AP-induced staggered transcriptional replacement either of the RNR M2 or of RNR M2b subunits, or other mechanisms is under investigation. This evidence concerns the gene NR2E3 and ovarian cancer.